Renalytix Plc (RENX.L)
RENX.L Stock Price Chart
Explore Renalytix Plc interactive price chart. Choose custom timeframes to analyze RENX.L price movements and trends.
RENX.L Company Profile
Discover essential business fundamentals and corporate details for Renalytix Plc (RENX.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Healthcare Information Services
IPO Date
6 Nov 2018
Employees
102.00
Website
https://renalytix.comCEO
James R. McCullough
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
RENX.L Financial Timeline
Browse a chronological timeline of Renalytix Plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Mar 2026
Upcoming earnings on 29 Sept 2025
Earnings released on 18 Mar 2025
EPS came in at -£0.03 falling short of the estimated -£0.01 by -175.48%, while revenue for the quarter reached £603.35K, missing expectations by -24.51%.
Earnings released on 30 Sept 2024
EPS came in at -£0.04 falling short of the estimated -£0.02 by -71.91%, while revenue for the quarter reached £436.35K, missing expectations by -28.82%.
Earnings released on 27 Sept 2024
EPS came in at -£0.04, while revenue for the quarter reached £497.84K, missing expectations by -93.69%.
Earnings released on 15 May 2024
EPS came in at -£0.07 falling short of the estimated -£0.04 by -90.35%, while revenue for the quarter reached £457.90K, missing expectations by -46.97%.
Earnings released on 15 Feb 2024
EPS came in at -£0.08 falling short of the estimated -£0.04 by -113.74%, while revenue for the quarter reached £615.86K, beating expectations by +2.68%.
Earnings released on 14 Nov 2023
EPS came in at -£0.09 falling short of the estimated -£0.04 by -115.80%, while revenue for the quarter reached £397.87K, missing expectations by -32.13%.
Earnings released on 28 Sept 2023
EPS came in at -£0.10 falling short of the estimated -£0.05 by -119.60%, while revenue for the quarter reached £445.85K, missing expectations by -93.41%.
Earnings released on 9 Jun 2023
EPS came in at -£0.12 falling short of the estimated -£0.05 by -173.73%, while revenue for the quarter reached £636.61K, missing expectations by -46.95%.
Earnings released on 30 Mar 2023
EPS came in at -£0.12 falling short of the estimated -£0.06 by -116.48%, while revenue for the quarter reached £1.05M, missing expectations by -1.47%.
Earnings released on 30 Nov 2022
EPS came in at -£0.14 falling short of the estimated -£0.05 by -164.72%, while revenue for the quarter reached £855.50K, missing expectations by -13.21%.
Earnings released on 30 Jun 2022
EPS came in at -£0.06 surpassing the estimated -£0.07 by +9.43%, while revenue for the quarter reached £715.77K, missing expectations by -53.52%.
Earnings released on 31 Mar 2022
EPS came in at -£0.17, while revenue for the quarter reached £684.43K.
Earnings released on 31 Dec 2021
EPS came in at -£0.18 falling short of the estimated -£0.06 by -200.74%, while revenue for the quarter reached £709.87K, beating expectations by +74.47%.
Earnings released on 21 Oct 2021
EPS came in at -£0.12, while revenue for the quarter reached £414.02K.
Earnings released on 30 Jun 2021
EPS came in at -£0.12, while revenue for the quarter reached £404.70K.
Earnings released on 31 Mar 2021
EPS came in at -£0.10, while revenue for the quarter reached £526.62K.
Earnings released on 31 Dec 2020
EPS came in at -£0.11, while revenue for the quarter reached £360.56K.
Earnings released on 27 Oct 2020
EPS came in at -£0.05.
Earnings released on 27 Oct 2020
EPS came in at -£0.09, while revenue for the quarter reached £562.63K.
RENX.L Stock Performance
Access detailed RENX.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.